Novavax aims for 2bn Covid vaccine doses

US drug developer Novavax Inc said on Tuesday it was doubling its potential Covid-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, sending its shares up about 7%. In August, Novavax signed a deal with Serum Institute to produce a minimum of one billion doses of its vaccine candidate.

Leave a Reply

Your email address will not be published. Required fields are marked *

Buy this website (including domain name) and introduce India to the world...

Contact the Seller!
X